Search

Objective: To investigate the expression levels of serum Epididymal protein 4 (HE4) and B7 homolog 4 (B7H4), as well as the relationship between systemic immune inflammation index (SII) and clinical pathological characteristics and tumor metastasis in ovarian cancer patients. Methods: 80 ovarian cancer patients admitted to our hospital from January 2017 to January 2020 were divided into malignant group, 80 patients with benign ovarian lesions in the same period were divided into benign group, and 80 healthy patients were selected as the control group. The serum expression levels of HE4, B7H4 and SII were compared in the three groups. The expression levels of HE4, B7H4 and SII in patients with tumor metastasis, and Spearman correlation between HE4, B7H4 and SII and the clinicopathological features of ovarian cancer and tumor metastasis. And followed up for 3 years, record the overall survival time, and analyze the relationship between HE4, B7H4 and SII and ovarian cancer survival. Results: There were differences in the expression levels of HE4, B7H4, and SII among the three groups of patients. The malignant group was significantly higher than the benign group and the control group (P<0.05); There was no difference in the expression levels of HE4, B7H4, and SII among ovarian cancer patients of different ages and histological types (P>0.05). However, there were differences in the expression levels of HE4, B7H4, and SII among patients with different FIGO stages, lymph node metastasis, distant metastasis, and tumor differentiation degree (P<0.05); The Spearman correlation analysis results showed that HE4, B7H4, and SII were not significantly correlated with the histological type of ovarian cancer, but were positively correlated with FIGO staging, lymph node metastasis, distant metastasis, and tumor differentiation degree(P<0.05); All patients were followed up for 4 years, and the median overall survival time of patients with high HE4 levels was 23.53 (6.42-42.13) months, which was lower than that of patients with low HE4 levels, which was 32.54 (14.53-42.13) months. The median overall survival time of B7H4 high-level patients was 21.32 (6.42-42.13) months, which was lower than that of low-level patients at 31.32 (14.63-42.13) months. The median overall survival time of patients with high-level SII was 20.36 (6.42-42.13) months, which was lower than that of patients with low-level SII at 34.68 (13.56-42.13) months(P<0.05). Conclusion: Serum expression of HE4, B7H4 and SII are correlated with clinical stage of ovarian cancer, lymph node metastasis, distant metastasis and degree of tumor differentiation, and high expression of the three may mean poor prognosis of patients. [ABSTRACT FROM AUTHOR]

Objective: To analyze the correlation between skeletal muscle mass index (ASMI) and TG/HDL-C in hospitalized elderly patients. To evaluate the predictive value of TG/HDL-C for low ASMI in elderly hospitalized patients. Methods: A total of 299 hospitalized elderly patients admitted to the First Hospital of Lanzhou University from July 2022 to August 2023 were selected and divided into low ASMI group (105 cases) and normal ASMI group (194 cases) according to the consensus on the diagnosis and treatment of sarcopenia issued by the Asian Working Group on sarcopenia in 2019. Clinical data of the two groups were compared, Spearman correlation analysis was used to study the correlation between ASMI and related variables, and multi-factor Logistic regression was used to analyze the influencing factors of ASMI. the predictive value of TG/HDL-C in the occurrence of low ASMI in elderly hospitalized patients was evaluate by receiver operating characteristic (ROC) curve. Results: With the increase of ASMI, TG/HDL-C ratio increased (P<0.001). Spearman correlation analysis showed that ASMI was positively correlated with waist-to-hip ratio, basal metabolism, muscle, grip strength, body fat percentage, BMI, ALT, TG, TG/HDL-C, and negatively correlated with HDL-C (P<0.05). Multifactor analysis showed that body fat percentage, uric acid and TG/HDL-C were independent influencing factors of ASMI. ROC curve showed that the area under TG/HDL-C curve was 0.67 (95% CI: 0.607~0.722). Conclusion: High TG/HDL-C was protective factors for low ASMI. TG/HDL-C has certain predictive value for the occurrence of low ASMI, and it is easy to estimate skeletal muscle mass by simple and easily obtained lipid indexes, so early monitoring and intervention can be carried out for patients with suspected sarcopenia. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore the clinical prognosis of 11011-operative patients with cerebral arteriovenous malformation. Methods: 129 patients with AVMs in the fust affiliated hospital of Harbin medical university from May 2015 to May 2017 were selected. 44 patients were treated with intravascular embolism. 43 patients were operated. 10 patients were treated with intravascular embolism and operation, and 32 patients were treated with non-operative treatment. All of the patients were fellow up for 1 year. The prognoses of different treatment groups were analyzed and compared. Results: After operation. 13 patients showed no symptom. 29 recovered and one died. With intravascular embolism. 22 patients showed 110 symptom. 21 patients recovered and one died. With operation and intravascular embolism, the numbers were 5. 4 and 1. In 11011-operative group. 11 patients showed no symptom. 22 recovered and 1 with acute cerebral hemorrhage. There was no statistically significant difference in the prognosis between different treatment groups (P> 0.05). Conclusions: No difference was observed between non-operative and other treatment therapies for the patients with arteriovenous malformation. More researches are needed for the pathogenesis and prognosis of arteriovenous malformation. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)